DEVELOPMENT, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC INTERNATIONAL HOLDING LTDDevelopment, Option and License Agreement • May 9th, 2012 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This DEVELOPMENT, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 3rd day of January, 2012 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and BIOGEN IDEC INTERNATIONAL HOLDING LTD, a Bermuda limited company, having its principal place of business at Canon’s Court, 22 Victoria Street, Hamilton HM12 Bermuda (“Biogen Idec”). Biogen Idec and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement.
